Enhanced Combination Therapies for Laminopathies, Cellular Aging, and Atherosclerosis

Improved combination therapies for treating laminopathies, cellular aging, and atherosclerosis, featuring sustained-release formulations, nanoparticle encapsulation, antioxidant co-administration, transdermal patch delivery, and tailored dosing regimens to enhance patient compliance, bioavailability, and treatment outcomes.

The original patent disclosed combination therapies for progeroid diseases and conditions, cellular aging, and cardiovascular and bone diseases. However, the original patent's limitations include poor patient compliance due to frequent dosing, limited bioavailability, and inadequate antioxidant protection. The new inventive concept addresses these limitations by introducing novel formulations, delivery methods, and dosing regimens to improve treatment outcomes and patient quality of life.

The enhanced combination therapies comprise a farnesyltransferase inhibitor and an mTOR inhibitor, administered in a sustained-release formulation to improve patient compliance. The farnesyltransferase inhibitor can be encapsulated in a nanoparticle to enhance bioavailability. Additionally, an antioxidant can be co-administered to reduce oxidative stress. Transdermal patch delivery and tailored dosing regimens based on patient age and disease severity can further improve treatment outcomes. The new inventive concept's components and operation are designed to overcome the limitations of the original patent, providing more effective and convenient treatment options for patients.

The new claims introduce novel formulations, delivery methods, and dosing regimens that are not obvious from the original patent. The sustained-release formulation, nanoparticle encapsulation, antioxidant co-administration, transdermal patch delivery, and tailored dosing regimens provide a significant improvement over the original patent, making the new inventive concept novel and non-obvious.

Alternative embodiments of the inventive concept could include other types of formulations, such as liposomal or microsphere-based delivery systems. Variations of the dosing regimens, including pulsatile or circadian-based dosing, could also be explored. Additionally, the inventive concept could be adapted for use in other disease areas, such as cancer or neurodegenerative disorders.

The enhanced combination therapies have significant commercial potential in the pharmaceutical industry, particularly in the areas of laminopathies, cellular aging, and atherosclerosis. The target market includes patients suffering from these diseases, as well as healthcare providers and researchers seeking more effective treatment options. The inventive concept's improved patient compliance, bioavailability, and treatment outcomes make it an attractive solution for the pharmaceutical industry.